A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

Also called NCT01628120

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 170 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01628120
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01628120. Allocation not applicable; no masking; primary purpose treatment. Start 2012-05-31 (actual); primary completion 2015-02-13 (actual). Results posted on 2018-07-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
Acronym
AiME - 04
Condition
Chronic Renal Failure Requiring Hemodialysis
Intervention (Biological)
Epoetin Hospira
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01628120
Content hash
db67842dbee15561dc6b7123ba99228c8cb855abcaec1322c6bc0171ad2d6c56